| BMS | Bachelor of Medical Science; betamethasone; biomedical monitoring system; biomedical science; bleomy... |
|---|---|
| PMA | index of prevalence and severity of gingivitis, where P = papillary gingiva, M = marginal gingiva, a... |
| BSN | baccalaureate of science in nursing; Bachelor of Science in Nursing; bowel sounds normal |
| DOS | day of surgery; deoxystreptamine; disk operating system; Doctor of Ocular Science; Doctor of Optical... |
| PDA | Patent Ductus Arteriosus; 동맥관개존증(動脈管開存症) ? CIx of Op 1. s... |
D factor
| pharmaceutical preparations | Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. (12 Dec 1998) |
|---|---|
| pharmaceutical services | Total pharmaceutical services provided by a qualified pharmacist. In addition to the preparation and distribution of medical products, they may include consultative services provided to agencies and institutions which do not have a qualified pharmacist. (12 Dec 1998) |
| pharmaceutical solutions | Homogeneous liquid preparations that contain one or more chemical substances dissolved, i.e., molecularly dispersed, in a suitable solvent or mixture of mutually miscible solvents. For reasons of their ingredients, method of preparation, or use, they do not fall into another group of products. (12 Dec 1998) |
| preservatives, pharmaceutical | Substances added to pharmaceutical preparations to protect them from chemical change or microbial action. They include antibiotics and antioxidants. (12 Dec 1998) |
| societies, pharmaceutical | Societies whose membership is limited to pharmacists. (12 Dec 1998) |
| insurance, pharmaceutical services | Insurance providing for payment of services rendered by the pharmacist. Services include the preparation and distribution of medical products. (12 Dec 1998) |
| economics, pharmaceutical | Economic aspects of the fields of pharmacy and pharmacology as they apply to the development and study of medical economics in rational drug therapy and the impact of pharmaceuticals on the cost of medical care. Pharmaceutical economics also includes the economic considerations of the pharmaceutical care delivery system and in drug prescribing, particularly of cost-benefit values. (12 Dec 1998) |
| fees, pharmaceutical | Amounts charged to the patient or third-party payer for medication. It includes the pharmacist's professional fee and cost of ingredients, containers, etc. (12 Dec 1998) |
| antibody technology | <molecular biology> Techniques for the synthesis of polyclonal and monoclonal antibodies for use in research, diagnostics and therapeutics. (09 Feb 1998) |
| assisted reproductive technology | Originally, a range of techniques for manipulating eggs and sperm in order to overcome infertility. Encompasses drug treatments to stimulate ovulation; surgical methods for removing eggs (e.g., laparoscopy and ultrasound-guided transvaginal aspiration) and for reimplanting embryos (e.g., zygot intrafallopian transfer (or ZIFT); in vitro and in vivo fertilization (e.g., artificial insemination and gamete intrafallopian transfer (or GIFT); ex utero and in utero foetal surgery; as well as laboratory regimes for freezing and screening sperm and embryos, and micromanipulating and cloning embryos. The field's first major success came in 1978 with the birth of "test-tube baby" Louise Brown, engineered by Steptoe, Edwards, et al., of England. As the technologies spread, they increasingly are being employed for purposes beyond infertility, i.e., to reduce the risk of, or avoid passing on, hereditary disease and to select for infant sex. Further uses that would aim at improving the "quality" of offspring have been widely discussed and raise profound legal and ethical questions. See: eugenics. (05 Mar 2000) |
| recombinant DNA technology | A series of procedures used to join together (recombine) DNA segments. A recombinant DNA molecule is constructed (recombined) from segments from 2 or more different DNA molecules. Under certain conditions, a recombinant DNA molecule can enter a cell and replicate there, autonomously (on its own) or after it has become integrated into a chromosome. (12 Dec 1998) |
| national centre for health care technology | A centre in the public health service which coordinates and administers a program of research, demonstrations, and evaluations of medical technologies and assessments of health care technology. (12 Dec 1998) |
| DNA technology, recombinant | A series of procedures used to join together (recombine) DNA segments. A recombinant DNA molecule is constructed (recombined) from segments from 2 or more different DNA molecules. Under certain conditions, a recombinant DNA molecule can enter a cell and replicate there, autonomously (on its own) or after it has become integrated into a chromosome. (12 Dec 1998) |
| technology | <study> Industrial science; the science of systematic knowledge of the industrial arts, especially of the more important manufactures, as spinning, weaving, metallurgy, etc. Technology is not an independent science, having a set of doctrines of its own, but consists of applications of the principles established in the various physical sciences (chemistry, mechanics, mineralogy, etc) to manufacturing processes. Origin: Gr. An art; cf. Gr. Systematic treatment: cf. F. Technologie. Source: Websters Dictionary (01 Mar 1998) |
| technology assessment, biomedical | Evaluation of biomedical technology in relation to cost, efficacy, utilization, etc., and its future impact on social, ethical, and legal systems. (12 Dec 1998) |